03_05 NSCLC metastatic without driver mutations

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

コンテンツは Talking About Tumors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、Talking About Tumors またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

1+ y ago 31:52

MP3•エピソードのホーム

1. Evidence to support platinum doublets
2. The tale of pemetrexed
3. Immune checkpoint inhibitors alone and in combination
4. Second Line, approach in progression

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Paz-Ares L et al. Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0

2. Hellmann MD et al. NEJM. 2019;381(21):2020-2031. doi:10.1056/NEJMOA1910231

3. Socinski MA et al. J Thorac Oncol. 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.009

4. Reck M et al. NEJM. 2016;375(19):1823-1833. doi:10.1056/NEJMOA1606774

5. Paz-Ares L et al. NEJM. 2018;379(21):2040-2051. doi:10.1056/NEJMOA1810865

6. Gandhi L et al. NEJM. 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005/

7. Scagliotti G et al. Oncologist. 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-0232

8. Paz-Ares L et al. Lancet Oncol. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3

9. Paz-Ares LG et al. JCO. 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.1102

10. Scagliotti GV et al. JCO. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375

11. Delbaldo C et al. JAMA. 2004;292(4):470-484. doi:10.1001/JAMA.292.4.470

12. Ardizzoni A et al. J Natl Cancer Inst. 2007;99(11):847-857. doi:10.1093/JNCI/DJK196

13. Temel JS et al. NEJM. 2010;363(8):733-742. doi:10.1056/NEJMOA1000678

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

03_05 NSCLC metastatic without driver mutations

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

published 1+ y ago